Introduction
Glucocorticoids (GC) are commonly used as anti-inflammatory or immunosuppressive treatments, and it has been estimated that 5-10% of children may require some form of GC therapy at some time in childhood [1] . Since the introduction of GCs in the treatment of rheumatoid arthritis in 1949, the therapeutic applications of these drugs have greatly broadened to encompass a large number of non-endocrine and endocrine diseases [2] . Despite intense efforts to maximise the beneficial effects and to minimise the side effects of GCs, adverse effects of GC medication are still common. Impairment of childhood growth with long-term GC was described nearly 50 years ago, however recent studies have shown that growth retardation can also occur with short-term GC therapy. In addition, it has been shown that the severity of side-effects may vary depending on the type of GC used [3, 4] .
Normal cartilage formation and bone growth is dependent upon chondrocyte progression through the growth plate as demonstrated by a number of null mutations that have been introduced in mice. Growth plate chondrocytes regulate the rate of longitudinal bone growth through the precise regulation of chondrocyte proliferation, hypertrophy and apoptosis [5, 6] . The mechanisms by which GC induce failure in the growth process are presently unclear but GCs act locally to inhibit longitudinal bone growth, suggesting a mechanism intrinsic to the growth plate. Baron and colleagues [7] reported that local infusion of GC into the growth plate decreased the ipsilateral tibial growth rate with no effects on the contralateral limb. In addition, both Silvestrini et al [8] and Smink et al [9] reported that GC reduced growth cartilage width, probably by inhibiting chondrocyte proliferation and increasing the apoptosis of terminal hypertrophic chondrocytes. Studies by ourselves [4, 10] and others are in agreement; reporting that GC impair chondrocyte proliferation and increase apoptosis [11, 12, 13, 14, 15] . The cellular machinery by which GC exerts control over chondrocyte dynamics is presently unclear but has been postulated to involve disruption to the growth hormone (GH) -insulin-like growth factor (IGF) axis. GH & IGF-I play essential roles in growth and development [16] with IGFs being mainly bound to IGF binding proteins (IGFBP) 1, 2 & 3 that reduce IGF bioavailability.
There is some conflicting evidence that GC effects on growth may be mediated via changes in GH sensitivity as well as changes in IGFBP expression [17] and IGF-I dependent phosphorylation events [18, 19, 20] Recently, a non-steroidal inflammatory agent (AL-438) that acts through the glucocorticoid receptor (GR) has been described [21] . Studies with AL-438 using the carrageenan-induced paw edema assay and the adjuvant arthritis models in rats have shown it retains full anti-inflammatory efficacy but has reduced negative effects on bone compared to those elicited by Prednisolone (Pred) [21] . It is presently unknown whether AL-438 has less detrimental effects on growth plate chondrocytes than other commonly used anti-inflammatory steroids. In this context, the effects of AL-438 have been compared with those of Dexamethasone (Dex) and Pred using the chondrogenic ATDC5 cell line and the fetal mouse metatarsal organ culture model. 
Materials and Methods

Chondrocyte cell culture
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki, Japan), and cells were cultured at a density of 6000 cells per cm 2 in differentiation medium in multi-well plates [25] (Costar, High Wycombe, UK). Differentiation medium contained DMEM/Ham's F12 (Invitrogen, Paisley, UK), 5% FCS (Invitrogen), 3x10 -8 M sodium selenite and 10µg/ml human transferrin (Sigma, Poole, UK) and insulin (10µg/ml; Sigma). Cells were incubated at 37 o C in a humidified atmosphere containing 5% CO 2 /95% air for up to 17 days and the medium was changed every second day after reaching confluency (day 6).
Gene expression
In order to study and compare the effects of AL-438 (Ligand Pharmaceuticals, San Diego, USA), Dex and Pred (Sigma) during both chondrogenesis (days 6-10) and terminal differentiation phases (days 13-17), all three compounds were added to the cells at the beginning of both time points (days 6 and 13, respectively) at a final concentration of 10 -6 M [4] in 0.01% dimethyl sulfoxide (DMSO). Control cultures contained 0.01% DMSO only. Cells were grown in the presence of the compounds for 4 days, at which point RNA was extracted, reverse transcribed and analysed for aggrecan gene expression by semiquantitative (sq) and quantitative (q) RT-PCR.
RNA extraction
Total RNA was extracted from chondrocytes by repeated aspiration though a 25gauge syringe needle in 1ml Ultraspec (Biotecx, Houston, Texas, USA). After extraction with chloroform, RNA in the aqueous phase was purified with isopropanol and bound to 50µl RNA Tack resin, before washing with 75% ethanol. The RNA was then eluted in 100µl nuclease free water and treated with DNase. For each sample the 260/280 ratio was determined, and the samples diluted to a concentration of 60ng/µl and stored at -80 o C. The control groups (0.01% DMSO only) and experimental groups contained 6 metatarsals each.
Semiquantative and Quantitative RT-PCR
Morphometric analysis
Images were taken of the metatarsals every second or third day of culture using a digital camera attached to a Nikon TE300 microscope ( 
Statistical Analysis
Data were analysed by one-way analysis of variance. All data are expressed as the mean ± S.E.M of at least 6 replicates within each experiment, and statistical analysis was performed using Minitab (Minitab 14; PA, USA). P<0.05 was considered to be significant.
Results
Effect of AL-438 on ATDC5 cell number and proliferation
During chondrogenesis exposure to Dex or Pred for 24h caused a concentration- 
Effect of AL-438 on proteoglycan production, ALP activity and expression of chondrocyte marker genes in ATDC5 cells
In comparison with control cultures during the chondrogenesis period, exposure to Dex and Pred for 96h caused a significant reduction in proteoglycan synthesis (56% and 54%, respectively; p<0.05), whereas exposure to AL-438 had no effect ( Figure  1c ). No significant differences between treatments were noted during terminal differentiation (data not shown). The effect of AL-438 on terminal chondrocyte differentiation was assessed by ALP activity. During chondrogenesis, ALP activity was significantly increased after exposure to Dex, Pred and AL-438 (p<0.05) ( Figure   1d ), but no significant differences were observed during terminal differentiation (data not shown). Semiquantitative PCR revealed that gene expression levels of aggrecan were reduced in Dex treated cells, but were unchanged in Pred or AL-438 treated cells (Figure 2a ). qPCR analysis confirmed a significant reduction in aggrecan expression with Dex (3.5-fold reduction; p<0.05), and also revealed a significant reduction in aggrecan with Pred (1.36-fold; p<0.05) (Figure 2b ). Caspase-3 activity was unchanged in Dex, Pred and AL-438 treated cells compared to controls during both chondrogenesis and terminal differentiation (data not shown). TNF-α did cause a significant increase in Caspase-3 activity as expected.
Anti-inflammatory efficacy of AL-438 in ATDC5 cells
LPS induced IL-6 production in ATDC5 cells and this induction was reduced by the co-incubation Dex or AL-438 by 58.1% and 55.4%, respectively. These results were significantly different (p<0.05) from IL-6 levels in LPS-only treated cells, but not significantly different from each other (p>0.05) ( Figure 3) . Interestingly, levels of IL-1 and TNF-α were undetected in control and test samples. These results demonstrate that AL-438 has a similar anti-inflammatory efficacy to Dex in ATDC5 cells.
Longitudinal bone growth and assessment of chondrocyte maturational zone sites
Until day 7 of culture, fetal mouse metatarsals treated with Dex or AL-438 grew at a similar rate to controls. However, subsequently, Dex treated metatarsals were significantly shorter than control bones (18.5% shorter at day 10 (p<0.05) and 22.2% shorter at day 12 (p<0.01)), whereas AL-438 treated metatarsals continued to parallel control bone growth (Figure 4) . The lengths of the proliferating, hypertrophic and mineralizing zones were measured on histological sections of 12-day-old metatarsals (Table 2; Figure 5 ). Although, the lengths of the proliferating and hypertrophic zones did not significantly change between treatments, Dex significantly reduced the length of the mineralizing zone (57%; p<0.05).
Cell proliferation in metatarsals: BrdU and PCNA staining
The number of proliferating chondrocytes within the metatarsals was significantly reduced by Dex (78.9%; p<0.05) and AL-438 (83.9%; p<0.05) ( Figure 6 ).
Interestingly, the majority of positive staining was observed within the cells of the perichondrium, with only a small number of proliferating chondrocytes being detected within the proliferative zone.
Discussion
Glucocorticoids are the most effective anti-inflammatory agents known. However, the long-term use of these steroids leads to a large number of side effects, including growth retardation in children. The exact mechanisms by which GC induce failure in the growth process are presently unclear, but early studies involving local infusion of GC directly into the growth plate decreased the ipsilateral tibial growth rate with no effects on the contralateral limb, suggesting a mechanism intrinsic to the epiphyseal growth plate [7] . It has also been shown that GC reduce growth plate cartilage width, and it has been suggested that this is due to GC inhibiting chondrocyte proliferation and increasing the apoptosis of terminal hypertrophic chondrocytes [8, 9] .
The search for a novel GC that has the anti-inflammatory properties of conventional steroids without one or more of the side-effects has been a long-standing goal of the field. Much effort has been spent on modifying the steroid backbone to achieve this, however, these efforts have been met with little success. Deflazacort, a D-ring substituted steroid, was originally hailed as a powerful anti-inflammatory molecule exhibiting reduced activity in bone and glucose metabolism [29] . Initially, clinical data supported this notion [30, 31] . However, subsequent trials that adjusted the steroid dose to maintain equivalent anti-inflammatory efficacy usually needed higher levels of deflazacort. Unfortunately, at these higher doses, the advantages of deflazacort disappeared. The field was revived by the discovery that in order to repress pro-inflammatory genes, the GR binds directly to specific transcription factors (NFκB and AP-1) which can up-or down-regulate inflammatory genes [32, 33] . This represented a unique mechanism that was genetically separable from transcriptional activation, and initiated the search for ligands that could induce transcriptional repression, but reduce transcriptional activation.
AL-438 is a specific, non-steroidal ligand for the GR that exhibits a unique profile and Dex and Pred may be due to the fact that AL-438 is qualitatively different in terms of its ability to activate or repress gene expression. Interestingly, none of the compounds had an effect on ATDC5 maturation in terms of proliferation, ALP activity or proteoglycan production during the terminal differentiation period, a finding that has been reported previously [4] .
The mechanism of action of AL-438 is based on the hypothesis that many genes involved in undesirable side effects are upregulated (such as enzymes in lipid and muscle metabolism), whereas many pro-inflammatory genes (i.e. IL-1, IL-6 and TNFα) are repressed. It has been hypothesised that upon binding to the GR, AL-438 induces structural changes in the receptor that are different than those induced by other GR ligands such as Pred or Dex [21] . These structural changes promote reduced co-factor interactions between the GR and co-factors such as PGC-1, which is involved in hepatic glucose production, but do not change the interactions between GRIP-1 and the GR, a co-factor which plays a role in the repression of proinflammatory genes [21] . This hypothesis may explain the reported maintenance of anti-inflammatory activity with AL-438 [21] but also its reduced effects on ATDC5 cells as found in this study. The proposed mechanism of action of AL-438 is also supported by the finding that as opposed to Dex, AL-438 does not have a detrimental effect on metatarsal bone growth. This finding confirms bone-sparing results from previous studies on rats treated with Pred or AL-438, which used calcein and tetracycline labelling to show that whilst Pred significantly reduced the rate of cortical bone formation, AL-438 had no effect [21] . The fact that the length of the mineralizing zone, but not the proliferating or hypertrophic zones, was significantly shorter in Dex treated bones suggests that Dex is acting directly on the terminally differentiated chondrocytes to reduce overall bone length. A similar finding has previously been found by our group [10] and others [37] , and may be caused by Dex interfering with genes involved in the mineralization process. The finding that Dex or AL-438-treated metatarsals had a similar number of proliferating chondrocytes was surprising when compared to the in vitro proliferation data, and could be explained by the suggestion that the activity of transcriptional activators such as AL-438 can vary under different conditions and in different tissue types [38] .
This data intriguingly suggests that bone growth within the metatarsal model is not wholly dependent on chondrocyte proliferation as growth retardation was not observed in the AL-438 treated metatarsals despite lowered proliferation. Other aspects of chondrocyte dynamics such as alterations in hypertrophy may be involved and this requires further investigation.
The finding that AL-438 maintains a similar anti-inflammatory efficacy to Dex in ATDC5 cells was important, as it proved that AL-438 was still fully efficacious as an anti-inflammatory agent in chondrocytes despite the fact that it was much less harmful than Dex or Pred. The anti-inflammatory efficacy of AL-438 has previously been demonstrated both in vivo using the rat carrageenan-induced paw edema assay and in vitro in HepG2 cells and human skin fibroblasts [21] .
To compensate for the fact that AL-438 is slightly less potent than Pred a saturating dose of 10 -6 M was used for all compounds in this study. In addition, this pharmacological concentration of Dex and Pred is similar to that found in chronic GC therapy and has been shown previously by us, and others, to inhibit both chondrocyte 
